Why Your Multivitamin Can’t Fix What Your Genes Won’t Allow: Understanding MTHFR
Understanding MTHFR
There is a pattern I see regularly in my practice.
Someone comes to me with a history of depression, anxiety, fatigue, brain fog, or unexplained body pain. These symptoms are often exacerbated around menopause or are due to a stressful life event. They’ve seen multiple doctors. Their standard bloodwork comes back “normal.” They’ve tried antidepressants — sometimes several different ones — with limited results or intolerable side effects. They’re eating reasonably well. They take a multivitamin or various supplements. They’re doing everything they’ve been told to do. And yet they still feel terrible.
In many of these cases, when we look at their genetics, we find the same thing: an MTHFR variant.
It doesn’t explain everything. But it explains a great deal. And more importantly, once you understand what MTHFR actually does — and what happens when it doesn’t work properly — you can begin to address the root cause rather than managing symptoms indefinitely.
That is what nutrigenomics is for.
What Is MTHFR?
MTHFR stands for methylenetetrahydrofolate reductase. I know — it’s a mouthful. But the concept behind it is truly quite elegant.
MTHFR is an enzyme. Its job is to convert folate from food into its active, usable form: 5-methyltetrahydrofolate, or 5-MTHF. This active folate is then used to perform one of the most critical biochemical reactions in your body — the conversion of homocysteine into methionine.
Methionine then becomes S-adenosylmethionine, known as SAMe — the universal methyl donor. SAMe powers over 200 methylation-dependent reactions throughout the body, including DNA methylation, neurotransmitter synthesis, hormone clearance, detoxification, and immune regulation.
Think of methylation as your body’s master switching system. It turns genes on and off. It makes neurotransmitters. It clears toxins. It repairs DNA. When methylation runs well, your biochemistry hums along. When it doesn’t — when there isn’t enough active folate and SAMe to drive these reactions — the consequences are felt across virtually every system in the body.
MTHFR is the enzyme that makes active folate available. It is the gateway.
The Two Key Variants: C677T and A1298C
The MTHFR gene has two well-studied variants — C677T and A1298C — that reduce the enzyme’s efficiency. These are not rare mutations. They are common genetic polymorphisms found across the global population.
C677T heterozygosity occurs in approximately 40% of the general population, with C677T homozygosity found in approximately 10–15%. Individuals with the homozygous TT genotype — meaning two copies of the C677T variant — have no more than 30% of normal enzyme activity. That means the enzyme that is supposed to produce active folate for your entire methylation system is operating at less than a third of its capacity.
A1298C has a smaller impact on its own than C677T, but compound heterozygosity — one copy of C677T plus one copy of A1298C — significantly reduces MTHFR activity, often more than a single homozygous C677T variant.
These are not edge cases. Taken together, a significant proportion of people walking around right now have meaningfully impaired methylation capacity — and most of them have no idea.
What Happens When MTHFR Doesn’t Work Properly
When the MTHFR enzyme is running at reduced efficiency, two things happen simultaneously, and both have far-reaching consequences.
Homocysteine accumulates. Without adequate active folate to drive the conversion of homocysteine to methionine, homocysteine builds up in the blood. Elevated homocysteine is considered an independent risk factor for cardiovascular disease, and the C677T polymorphism is thought to be the most common genetic cause of elevated homocysteine levels. High homocysteine is also toxic to neurons and blood vessels, contributing to cognitive decline, vascular damage, and systemic inflammation over time.
SAMe production falls. Less active folate means less methionine, and less methionine means less SAMe. And less SAMe means every methylation-dependent process in the body slows down. SAMe is directly involved in the synthesis and metabolism of dopamine, norepinephrine, and serotonin — neurotransmitters postulated to play an important role in the pathogenesis of depression and anxiety.
This is the part that most conventional medicine misses entirely. When a doctor sees a patient with depression or anxiety and reaches for a prescription, they are attempting to manage neurotransmitter levels at the synapse. What they are not asking is: why isn’t the brain producing enough of these neurotransmitters in the first place? In many cases, the answer is insufficient methylation capacity — and MTHFR is at the root of it.
MTHFR is needed to convert homocysteine into methionine, which is then used to make neurotransmitters such as serotonin, norepinephrine, and dopamine. If there is a shortage of these neurotransmitters, you are at greater risk of developing mood disorders such as depression and anxiety.
SAMe is also involved in making GABA — the inhibitory neurotransmitter that helps reduce anxiety and promote feelings of calm. When methylation is impaired, GABA production can also fall — which helps explain why so many people with MTHFR variants struggle with chronic anxiety, nervous system hyperactivity, and difficulty sleeping.
The Folic Acid Problem
Here is where I need to be direct about something that is causing real harm: taking standard folic acid when you have an MTHFR variant is not just unhelpful — it can actively make things worse.
Folic acid is the synthetic form of folate found in most multivitamins, prenatal vitamins, and fortified foods. Unlike natural food folate, folic acid requires conversion through several enzymatic steps before it can become the active 5-MTHF your body actually uses. One of those steps requires — you guessed it — the MTHFR enzyme.
If your MTHFR enzyme is functioning at 30% capacity, it cannot efficiently convert folic acid into its active form. When this conversion does not happen properly, folic acid can accumulate in the body as unmetabolized folic acid (UMFA) in the bloodstream — a buildup that has been linked to depression, bipolar disorder, schizophrenia, and heart disease.
So the very supplement that millions of people with MTHFR variants are taking — in their prenatal vitamins, their daily multivitamins, the fortified cereals they eat — may be contributing to their symptoms rather than resolving them.
The solution is not more folic acid. The solution is bypassing the broken conversion step entirely by supplementing with 5-MTHF directly — the active form the body can use without needing MTHFR to convert it. This is a fundamental principle of nutrigenomics: know your genetics, then give the body what it actually needs in the form it can actually use.
The Cofactors Most People Don’t Know About
MTHFR does not work in isolation. Like all enzymes, it requires specific cofactors to function. Two in particular are critically important and frequently overlooked.
Riboflavin (Vitamin B2) is the precursor to FAD — flavin adenine dinucleotide — which is the direct cofactor for the MTHFR enzyme itself. The MTHFR 677T variant changes the structure of the enzyme, reducing the ability of the FAD cofactor to bind, which is one of the reasons this variant causes the enzyme to work so poorly. Research published in Circulation found that higher riboflavin intakes can contribute to neutralizing the effect of the C677T genetic variant on homocysteine levels — making riboflavin one of the most underappreciated tools in supporting methylation in people with this variant.
Vitamin B12 — specifically in its active forms, hydroxocobalamin or adenosylcobalamin — works alongside active folate in the methylation cycle. Without adequate B12, the cycle cannot be completed. This is why the standard recommendation of methylcobalamin needs to be approached carefully in people who also carry COMT variants (which affect neurotransmitter clearance) — a nuance that only becomes visible when you look at the full genetic picture.
Vitamin B6 (as P5P) supports the alternative pathway for homocysteine clearance through the transsulphuration route and is essential for neurotransmitter synthesis. It is a key supporting player throughout the methylation network.
Magnesium is required for hundreds of enzymatic reactions throughout the body, including those involved in methylation and detoxification. Many people with MTHFR variants are also chronically low in magnesium — which compounds the problem significantly.
Why This Changes Everything About Supplementation
Here is what this means in practice, and why I approach supplementation the way I do.
For someone with an MTHFR variant, a standard multivitamin containing folic acid is the wrong tool. A protocol built around active folate (5-MTHF), riboflavin, B12 in active forms, B6 as P5P, and magnesium — dosed appropriately for the individual — is a completely different intervention. Not just better. Fundamentally different in mechanism.
This is also why I approach methylation support with care rather than aggression. Pushing high-dose methylfolate into a system that also has COMT variants can actually overstimulate the system. Unfortunately, this is case with many of my clients when they come to me, whose nutrigenomics reports showed both MTHFR and COMT variants together. The COMT enzyme is responsible for breaking down catecholamines like dopamine and noradrenaline. When it is slow, these neurotransmitters linger longer than they should, contributing to anxiety, overwhelm, and nervous system hyperactivity. Flooding that system with high-dose methylating nutrients without understanding the full picture can make anxiety significantly worse.
This is precisely why I use niacinamide — vitamin B3 — as a methylation buffer in cases where there is both MTHFR impairment and COMT slowness. Niacinamide supports NAD metabolism and gently buffers methylation activity without provoking adrenergic stress. It is a gentler, more intelligent approach — one that is only possible when you know what the genes are actually showing you.
Nutrigenomics is not about having a variant and taking a supplement. It is about understanding the entire biochemical picture, seeing where the bottlenecks are, and supporting the system in the correct sequence with the correct forms and doses.
Signs That MTHFR May Be Playing a Role for You
No two people with MTHFR variants present identically. But there are patterns I see repeatedly in clinical practice that suggest methylation may be a significant factor:
- Depression or anxiety that has not responded well to antidepressants, or that required multiple medication trials
- Chronic fatigue that doesn’t resolve with sleep
- Brain fog, poor memory, or difficulty concentrating
- History of pregnancy complications, miscarriage, or neural tube defects in a child
- Elevated homocysteine on a blood panel (even mildly elevated deserves attention)
- Sensitivity to medications that affect neurotransmitters or liver enzymes
- Adverse reactions to high-dose methylfolate or methylcobalamin supplements
- Family history of cardiovascular disease, stroke, or dementia
- History of mood disorders across family members
Any of these alone is not diagnostic. But as a pattern, they point toward a methylation story worth investigating.
What You Can Do
The first step is knowing your status. MTHFR variants can be identified from a raw DNA file from services like 23andMe or AncestryDNA — which means you may already have the data you need. The next step is understanding what your specific variants mean in context: not just which variants you carry, but how they interact with each other, with your other genes, and with your current nutrient status.
A serum homocysteine test is one of the most useful clinical markers. If your homocysteine is elevated — even mildly — it is a signal that your methylation cycle is under pressure. It is a biomarker you can track over time as you make nutritional and supplementation changes.
From there, a targeted protocol built around your specific variant status, your symptoms, and your full genetic picture can begin to genuinely address the root cause — rather than cycling through medications that address the downstream effects of a methylation problem without ever touching the problem itself.
This is the work I find most meaningful. Not because it is complicated for its own sake, but because when someone finally understands why they have felt the way they have felt for years — and then begins to actually feel better — that is transformational in a way that symptom management never is.
A Final Word on Nutrigenomics
MTHFR is one of the most studied and well-understood gene variants in functional medicine. But it is never the whole story. It sits within a network of genes — COMT, GSTP1, SOD2, PEMT, FADS2, IL10, and many others — each of which influences how your body processes nutrients, clears toxins, regulates inflammation, and produces the molecules that determine how you feel every day.
What nutrigenomics makes possible is a view of that entire network. Not a single gene in isolation, but the full pattern — the strengths, the vulnerabilities, the interactions — so that a protocol can be built that works with your biology rather than against it.
That is what personalized medicine was always supposed to be.
Brigitte Spurgeon works remotely with clients across the US, Canada, Europe, Africa, Asia, and Australia. Her work integrates functional genomics, orthomolecular medicine, and targeted nutrition to address the root causes of chronic disease. To learn more about nutrigenomics reporting and personalized protocols, visit www.brigittespurgeon.com.
This article is for educational purposes and does not constitute medical advice.
